Global Proteasome Inhibitors Market: About this market
Proteasome inhibitors are used for the treatment of multiple myeloma. This proteasome inhibitors market analysis considers sales from VELCADE, KYPROLIS, NINLARO, and other products segments. Our analysis also considers the sales of proteasome inhibitors in Asia, Europe, North America, and ROW. In 2018, the VELCADE segment held the highest market share, which is expected to remain prevalent over the forecast period. The drug is the first proteasome inhibitor to receive approvals from the FDA and EMA. Moreover, the drug is the most effective in treating multiple myeloma. These factors will significantly help the VELCADE segment in maintaining its leading market position. Also, our global proteasome inhibitors report has observed market growth factors such as the huge unmet need, strong adoption rate, and growing incidence of myeloma. However, the threat from biologics, strong adverse effects, and slow regulatory approval may hamper the growth of the proteasome inhibitors industry over the forecast period.
Global Proteasome Inhibitors Market: Overview
Huge unmet need
There is a significant unmet treatment need for myeloma and a few solid tumor indications. Vendors are leveraging this situation and are focusing on developing therapeutics for the same. The market also has only a few approved therapies. As a result, there is significant scope for vendors to expand into the market. Therefore, the huge unmet need and the rising incidence of cancer will propel the growth of the global proteasome inhibitors market over the forecast period. The market is expected to record a CAGR of about 8% during the forecast period.
Apart from treating myeloma and solid tumors, proteasome inhibitor drugs are also being used to cure non-oncology conditions. For instance, ACU-D1 is a novel proteasome inhibitor that is proven to treat rosacea. The drug is in its second phase of clinical studies. There is ongoing research on expanding applications of proteasome inhibitor drugs to treat other conditions. This factor will have a positive impact on the overall market growth.
With the presence of a few major players, the global proteasome inhibitors market is concentrated. This robust vendor analysis is designed to help clients in improving their market positions, and in line with this, this report provides a detailed analysis of several leading proteasome inhibitors producers, which include Allergan Plc, Amgen Inc., Celgene Corp., Johnson & Johnson Services Inc., and Takeda Pharmaceutical Co. Ltd.
Also, the proteasome inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Our reports have been used by over 10K customers, including:
126 pages •
By Global Industry Analysts
• Mar 2021
- StrategyR - A Trademark of Global Industry Analysts, Inc.
- Project Edition: 8
- Influencer Pool: 1249
- MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies....
The oncology information systems market is projected to reach USD 9.5 billion by 2025 from USD 6.7 billion in 2020, at a CAGR of 7.4% during the forecast period. Growth of the market is mainly attributed to the technological advancements; increasing incidences of cancer cases, and growing public and private investments, funding, and grants...
200 pages •
By The Business Research Company
• Dec 2020
Major players in the immuno-oncology drugs market are Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., F. Hoffmann-La Roche AG, Johnson & Johnson, Novartis International AG, and AbbVie Inc. The global immuno-oncology drugs market is expected to decline from $59.64 billion in...
915 pages •
By Global Industry Analysts
• Sep 2020
The global market for Cancer Therapies is projected to reach US$220.5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease. Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed...
120 pages •
By Infiniti Research Limited
• Nov 2020
Global Bone Cancer Drugs Market 2020-2024
The analyst has been monitoring the bone cancer drugs market and it is poised to grow by $ 911.76 mn during 2020-2024, progressing at a CAGR of 5% during the forecast period. Our reports on the bone cancer drugs market provide a holistic analysis, market size and forecast, trends,...
Global beta glucan and fucoidan market is projected to grow at a CAGR of 8.08% during the forecast period (2020-2025) - The growing application of beta-glucan and fucoidan in nutraceutical supplements is majorly driving the market growth across the globe. Evolved consumer trends and rising demand for immunity booster foods and diets...
Bone Cancer Treatment Market Report Overview Bone Cancer Treatment market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Bone Cancer Treatment market types and applications. It is a focused study on Bone Cancer Treatment market space including...
Urothelial Cancer Drugs Market Report Overview Urothelial Cancer Drugs market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Urothelial Cancer Drugs market types and applications. It is a focused study on Urothelial Cancer Drugs market space...